How arginine deprivation starves a tumour
Every cell needs arginine to build proteins, divide and signal. Healthy cells make it. Many cancer cells cannot. The therapy uses that difference.
Why tumours depend on it
Arginine is made in the urea cycle, a chain of enzymes that every healthy cell carries. Two of these enzymes, ASS1 and OTC, are the bottleneck. Switch them off and the cell can no longer produce arginine; it has to import it from the blood.
Many cancers do exactly that. They silence ASS1 because it competes with the fast growth they favour: without ASS1, the raw material aspartate is diverted into building DNA instead of arginine. The tumour grows faster, but at a price. It becomes dependent on an external supply of arginine, a state called arginine auxotrophy.
ASS1 loss has been documented in roughly half or more of mesotheliomas, hepatocellular carcinomas, melanomas and sarcomas, and in substantial shares of pancreatic, prostate, bladder, small-cell lung and some breast cancers, as well as in some leukaemias. OTC loss adds further tumour types. Which tumours are affected can be measured in a biopsy with a routine stain.
What Argeon does in the blood
Argeon is a recombinant mammalian arginase. Given every 14 days, it circulates in the blood and converts arginine into ornithine and urea, both harmless, both excreted. Within hours of the first dose, arginine in the blood falls below the detection limit and stays there.
Earlier enzymes for the same purpose had two problems. ADI-PEG 20, a bacterial enzyme, is recognised as foreign; most patients form antibodies after about eight weeks and the drug stops working. Pegzilarginase, a human enzyme, is well tolerated but short-lived. Argeon is built to fix both: a mammalian protein with low immunogenicity, fused to an albumin-binding domain that keeps it in circulation for days rather than hours and shields it from antibodies and from being filtered out by the kidneys.
What happens inside a starved cancer cell
A cancer cell without arginine does not simply stop. It runs a survival programme that evolved for short famines. Stretched over months, that programme destroys it.
The cell's healthy neighbours experience none of this. They make their own arginine, their mTORC1 stays on, and they continue their normal work.
Why six months and not six weeks
A person can fast for three days without harm; after a week it becomes dangerous. Cancer cells are tougher. They enter a low-energy dormancy and recycle their own parts. Weeks of deprivation are not enough; months are.
Growth stops
Arginine gone within hours. mTORC1 off, AMPK on. Tumour cells stop dividing and conserve energy. Nothing visible yet on imaging.
Cells consume themselves
Self-digestion keeps cells alive at the cost of their own mitochondria. Oxidative stress rises. Tumour markers in the blood often begin to fall in this window.
Open to combined therapy
Depleted cells have thinner reserves and leakier membranes. Low-dose chemotherapy, checkpoint inhibitors or radiation now hit harder than they would alone. First imaging review at week 8.
Cell death and clearance
Reserves exhausted, DNA damaged, cells die. The immune system clears debris and surviving cells. Reviews at weeks 16 and 24 decide whether to stop, pause or extend.
The sequence is a model built from laboratory data and early clinical observation. Individual courses differ. Some patients show marker changes within weeks, others later or not at all.
Why the immune system needs time
Your immune system finds and destroys cancer cells every day of your life. It loses in advanced disease for one reason: the tumour makes new cells faster than the immune system can remove them.
Arginine deprivation attacks that ratio from both sides. Growth stops, so there are no new cells to clear. Starved cells become stressed and display more of the damage signals that natural killer cells and T cells recognise. T cells also need arginine themselves; how much systemic depletion helps or hinders the immune response in a given patient is an open question, and one reason combinations with checkpoint inhibitors are studied rather than assumed. What is certain is the time: an immune system no longer outpaced by growth gets to do what it was already trying to do.
This is why the course lasts 24 weeks. The enzyme holds the tumour still. The destruction is done by the body and, where your oncologist chooses, by therapies combined with it.
What happens to healthy cells
Healthy cells carry a working urea cycle. When arginine disappears from the blood, they make it from citrulline, which the enzyme does not touch. Liver, kidney, muscle and immune cells all keep their supply.
Some functions are sensitive. Arginine is the raw material for nitric oxide, which widens blood vessels, and it plays a role in wound healing and in the activity of some immune cells. In trials of related enzymes these effects were mild and reversible: occasional changes in blood pressure, slower healing of existing wounds. Both are monitored. Patients with a pre-existing urea-cycle disorder, who cannot make arginine themselves, are excluded for exactly this reason.
How a tumour can escape, and how we watch for it
A tumour under arginine pressure has one way out: switch ASS1 back on. Some do, through demethylation of the gene's promoter, often driven by the oncogene c-Myc. When that happens the tumour regains its own supply and the enzyme loses its grip.
Two things limit this. First, re-expressing ASS1 costs the tumour the growth advantage it gained by silencing it, so resistant tumours tend to grow more slowly. Second, resistance takes time to emerge, and the window before it does is exactly where combined therapies are most effective. Tumour markers, imaging at weeks 8, 16 and 24, and, where used, circulating tumour cell counts, show whether the tumour is still responding. If it is not, treatment stops.
Why combinations work better
A cancer cell with depleted energy, failing mitochondria and damaged DNA is a cell with fewer defences. Drugs that it would normally pump out, repair after, or outgrow now reach their target. Arginine deprivation does not replace standard treatment; it makes it more effective.
All combinations are decided by your treating oncologist, who stays in charge of your standard therapy throughout.
How it compares
| Chemotherapy | Immunotherapy | Radiation | Arginine deprivation | |
|---|---|---|---|---|
| Acts on | all dividing cells | immune checkpoints | one treated field | cells that cannot make arginine |
| Reach | systemic | systemic | local | systemic |
| Healthy tissue | affected (blood, hair, gut) | autoimmune effects possible | within the field | largely spared |
| Typical side effects | nausea, hair loss, infections | fatigue, inflammation | local skin and organ effects | fatigue, injection-site reaction |
| Combinable with arginine deprivation | yes, often at lower dose | yes | yes | — |